FDA will undertake steps to accelerate the process of developing biosimilars, while also reducing development costs. 

Read this month’s pharma news roundup, featuring brain-computer interfaces, a new world record and a cost-effectiveness conundrum.

The UK government has extended the deadline for organisations to submit notice to leave the scheme by two weeks.

Novartis to acquire Avidity Biosciences for $12bn, boosting its RNA neuromuscular pipeline as pharma M&A heats up in the RNA space.

Google’s Quantum Echoes breakthrough could revolutionise drug discovery, offering faster, more precise ways to design new medicines.

CSL Seqirus real-world study finds cell-based flu vaccines offer stronger protection than egg-based options in 2023/24 season.

Lundbeck is partnering with Contera Pharma to accelerate RNA-targeted drug discovery for serious neurological conditions.

Injectable HIV PrEP marks a breakthrough in prevention, providing a new option for patients in England unable to take daily pills.

Roche has set a new Guinness World Record for the fastest DNA sequencing of a human genome, marking a major milestone in genomic innovation. 

AstraZeneca joins Trump’s drug pricing plan, pledging $50bn US investment and discounts of up to 80% to cut prescription medicine costs.

The UK’s NIHR has invested £1.5M in digital health to cut paediatric mental health waiting times.

A new biotech company in New York, Nilo Therapeutics, believes the brain could hold the key to treating immune diseases.

ABPI calls for NICE to raise its cost effectiveness threshold for new medicine, which hasn’t raised in 20 years and is not linked to inflation.

New research from Precision Neuroscience shows its brain-computer interface can record high-resolution signals without invasive surgery.

UK pharma and healthcare stocks drive FTSE 100 to a record high, led by AstraZeneca, as trade policy shifts boost investor confidence.

Read this month’s pharma news roundup, featuring AI in healthcare risks, GLP-1 drug trials beyond obesity and Trump’s US tariffs.

England’s NHS is launching NHS Online, a fully digital hospital, to speed up specialist appointments, cut wait times and improve care access.

Donald Trump has threatened sweeping new trade measures on the pharma sector unless manufacturers commit to producing in the US.

Sanofi has committed $625m to its corporate venture capital arm, Sanofi Ventures, for funding biotech and digital health companies.

Pfizer is claiming a space in the global obesity market as it announces plans to acquire weight loss drug developer Metsera for $4.9bn.

Roche acquires 89bio in a $3.5bn deal, adding a late-stage MASH therapy and expanding its focus on cardiovascular and metabolic diseases.

Patients are increasingly turning to ChatGPT for medical advice, but new research warns it isn’t yet accurate enough to be relied on alone.

Phesi analysis shows GLP-1 therapies moving beyond diabetes and obesity into 100+ diseases, from cancer to cardiovascular conditions.

The latest ABPI and PwC Pharmaceutical Competitiveness Framework reveals the UK is losing ground in pharma R&D, investment, and clinical trials, with rankings slipping sharply since 2018.

Novo Nordisk announces 9,000 job cuts to streamline operations and reinvest in diabetes and obesity growth, aiming for long-term efficiency.

Lilly has launched TuneLab, giving biotech companies access to AI-powered drug discovery models based on over £1bn in research investment.

MSD has agreed to acquire UK biopharma company Verona Pharma in a $10bn deal, strengthening its cardio-pulmonary care portfolio.

A group of 300 middle schoolers are named in the 2025 Thermo Fisher Junior Innovators Challenge for STEM projects in AI to climate change.

The National Institute for Health and Care Research (NIHR) is funding Newcastle Univeristy’s work in emerging diagnostics, devices and more.

A £29.6 million government investment will establish the UK RNA Biofoundry in Darlington, providing manufacturing capacity to accelerate RNA therapies from lab to clinic.

Novo Nordisk partners with Replicate Bioscience in a $550M srRNA deal to develop new therapies for obesity, diabetes and cardiometabolic diseases.

From the latest in clinical evidence to new investments, there’s plenty to uncover.

AbbVie has announced the acquisition of Gilgamesh Pharmaceuticals’ lead investigational drug – a next-generation psychedelic compound for moderate-to-severe major depressive disorder.

NICE unveils new type 2 diabetes guidance, promoting earlier access to advanced therapies such as SGLT-2 inhibitors and more.

Novartis is partnering with Atropos Health to develop AI models that accelerate rare disease diagnosis, starting with a rare blood disorder.

HonorHealth appoints Dr Nicholas Schork to lead AI-driven disease interception research, reflecting an industry shift towards prevention.

AstraZeneca and Viseven win the 2025 HBA ACE Awards for innovative workforce and community programmes shaping the future of healthcare.

AbbVie to invest $195m in manufacturing expansion as pharma rushes to boost domestic capacity ahead of expected drug import tariffs.

Bayer announces deal with Kumquat for a pancreatic cancer KRAS inhibitor, plus, promising mRNA vaccine research emerges from Phase 1 trial.

Ireland could become a global leader in FemTech innovation, but only if it acts now, claims a new report by Health Innovation Hub Ireland.

A patient case study has uncovered a potential link between beta-HPV and the common skin cancer, cutaneous squamous cell carcinoma (cSCC).

NHS launches the first gonorrhoea vaccine programme in England to reduce infections and tackle the rise of antibiotic resistance.

Two major health agencies are facing leadership reshuffles, with the resignations of the FDA’s Vinay Prasad and NICE’s Dr Sam Roberts. 

From concerning statistics on global health outcomes to new insights on AI and RWD, there’s plenty to discover.

Explore the evolving role of MDMA, LSD and psilocybin in traditional medical research, particularly in the realm of mental health.

Bristol Myers Squibb announces the appointment of Dr Cristian Massacesi as Executive Vice President, Chief Medical Officer and Head of Development.

Laura McMullin, General Manager, Daiichi Sankyo UK, has been appointed the new Vice President of the ABPI.

WHO and UNICEF report finds that global childhood vaccination coverage held steady in 2024, but that worrying gaps remain.

A new survey has found that the use of AI and real-world data (RWD) is on the rise across the biopharma industry, but hurdles remain.

While genomics is best known for its role advancing precision medicine, MGI Tech has pioneered a new use case in enviromental sustainability.

UNAIDS report warns the US funding collapse could risk millions of new infections and deaths unless countries transform their HIV responses.

Sanofi is sponsoring the event for the second year in a row, which brings together 1,000 transplant recipients and live donors to compete.

A report has found that while many in the UK live with rare diseases, systemic failures continue to restrict progress in treatment.

Explore the latest technology that is changing the pharma industry, and discover how these innovations could solve key health challenges.

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round up.

Rising one place to number one overall, the British drugmaker has overtaken the NHS as the preferred destination for these graduates.